X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Data shows that after more than five years of median follow-up (65.4 months), PFS remained significantly superior among patients treated with the VENCLEXTA (Venetoclax) and obinutuzumab combination compared to the chlorambucil and obinutuzumab chemotherapy regimen.
Lead Product(s): Venetoclax,Obinutuzumab
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
EMWA 2024
Not Confirmed
Contact SupplierDetails:
VENCLEXTA®/VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
EMWA 2024
Not Confirmed
Contact SupplierDetails:
VENCLEXTA®/VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclyxta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
In addition, assessment in peripheral blood 30 months after the end of treatment showed that 26.9% of patients treated with VENCLEXTA (venetoclax) still had undetectable MRD (<10-4) compared with 3.2% of patients in the study arm who received obinutuzumab plus chlorambucil.
Lead Product(s): Venetoclax,Obinutuzumab
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Ibrutinib plus venetoclax is an investigational fixed-duration combination. Patients received 3 cycles of ibrutinib lead-in followed by 12 cycles of ibrutinib + venetoclax (Ibr 420 mg/day PO; Ven ramp up to 400 mg/day PO).
Lead Product(s): Venetoclax,Ibrutinib
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Latest data from the CAPTIVATE study underscore that IMBRUVICA in an all-oral fixed-duration combination with venetoclax also delivers a high rate of progression-free survival at two years while enabling treatment-free remission for patients.
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Positive opinion based on data from the VIALE-A and M14-358 trials, which evaluated the safety, efficacy and pharmacokinetics of VENCLYXTO in combination with hypomethylating agents in adult patients with AML.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclyxto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
In the VIALE-A trial, the median overall survival of patients who received VENCLEXTA plus azacitidine was 14.7 months (11.9, 18.7) vs 9.6 months (7.4, 12.7) in patients who received azacitidine in combination with placebo.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Phase 3 MURANO trial shows median progression-free survival of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab Vs. 17.0 months in patients taking bendamustine plus rituximab after three years or more off treatment.
Lead Product(s): Venetoclax,Rituximab
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
The results show the ibrutinib plus venetoclax combination providing continued disease-free survival for CLL patients once treatment is complete.
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
AbbVie will present updated results from the CAPTIVATE study, evaluating disease-free survival in previously untreated patients with chronic lymphocyctic leukemia/small lymphocytic leukemia who received ibrutinib (IMBRUVICA®) + venetoclax (VENCLEXTA®/ VENCLYXTO®) regimen.
Lead Product(s): Venetoclax,Ibrutinib
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
The FDA approval of VENCLEXTA for newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a series of trials including two Phase 3 trials - VIALE-A (M15-656) and VIALE-C (M16-043).
Lead Product(s): Venetoclax,Cytarabine
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo.
Lead Product(s): Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
AbbVie to present data from the CLL14 trial evaluating venetoclax in combination with obinutuzumab in patients with previously-untreated CLL and Extended follow-up from subgroup-analyses of MURANO trial of venetoclax in combination with rituximab in relapsed/refractory CLL.
Lead Product(s): Venetoclax,Obinutuzumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
AbbVie and Roche’s Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.
Lead Product(s): Venetoclax,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Study did not demonstrate statistically significant improvement in the primary endpoint of overall survival (OS) (Hazard Ratio [HR]=0.75, [95% CI 0.52 - 1.07], p=0.11)
Lead Product(s): Venetoclax
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
EMWA 2024
Not Confirmed
Contact SupplierDetails:
The data reinforce the potential of IMGN632 as a new therapy for patients with relapsed/refractory AML and result showed that they manageable safety profile and 38% composite complete remission rate seen in the higher intensity cohorts.
Lead Product(s): IMGN632,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: IMGN632
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
The data demonstrate the promising anti-leukemia activity and manageable safety profile of the IMGN632 triplet in AML, and we are encouraged by its potential in patients with relapsed/refractory AML, where well-tolerated, effective options remain quite limited.
Lead Product(s): IMGN632,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: IMGN632
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Imbruvica (ibrutinib) is a USFDA approved Bruton’s tyrosine kinase inhibitor. It is being evaluated in combination with venetoclax for the treatment of relapsed/refractory mantle cell lymphoma.
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Imbruvica (ibrutinib) is a USFDA approved Bruton’s tyrosine kinase inhibitor. It is being evaluated in combination with venetoclax for the treatment of chronic lymphocytic leukemia.
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
EMWA 2024
Not Confirmed
Contact SupplierDetails:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): SLS009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
ME-522 (voruciclib), an investigational selective oral CDK9 inhibitor, in combination with venetoclax (Venclexta®), a BCL2 inhibitor is being evaluated for the treatment of relapsed and refractory acute myeloid leukemia.
Lead Product(s): Voruciclib,Venetoclax
Therapeutic Area: Oncology Product Name: ME-522
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
FP-1305 (bexmarilimab) is a first-in-class, humanized monoclonal antibody, which binds to Clever-1, an immunosuppressive receptor found on macrophages. It is being evaluated for the treatment of higher-risk (HR) myelodysplastic syndrome.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.
Lead Product(s): Radgocitabine,Venetoclax
Therapeutic Area: Oncology Product Name: DFP-10917
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor. It is being evaluated in combination with venetoclax for the treatment of higher-risk myelodysplastic syndromes & chronic myelomonocytic leukemia.
Lead Product(s): Decitabine,Cedazuridine,Venetoclax
Therapeutic Area: Oncology Product Name: Inqovi
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
IO-202 is a first-in-class antagonist antibody with specific, high affinity binding to LILRB4. It is being evaluated for the treatment of relapsed or refractory chronic myelomonocytic leukemia.
Lead Product(s): IO-202,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: IO-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
GS-4721 (magrolimab) is a monoclonal antibody targeting CD47. It is being evaluated in phase 3 clinical trials for the treatment of TP53 mutant acute myeloid leukemia.
Lead Product(s): Magrolimab,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GS-4721
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
Idhifa (enasidenib) is an isocitrate dehydrogenase-2 inhibitor, which is being evaluated in combination with venetoclax for the treatment of IDH2 gene mutated acute myeloid leukemia.
Lead Product(s): Enasidenib,Venetoclax
Therapeutic Area: Oncology Product Name: Idhifa
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor. It is being evaluated in phase 2 clinical trials in combination with venetoclax for the treatment of patients with relapsed/refractory AML.
Lead Product(s): RVU120,Venetoclax
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
The net proceeds will be used for the manufacturing and clinical trials of potent inhibitor known as HM43239 (tuspetinib) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hanmi Pharmaceutical
Deal Size: $13.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 31, 2024
Details:
Xospata (gilteritinib) is a small molecule that inhibits multiple receptor tyrosine kinases, including FLT3. It is being evaluated in combination with venetoclax & azacitidine for the treatment of relapsed/refractory acute myeloid leukaemia with a FLT3 mutation.
Lead Product(s): Gilteritinib Fumarate,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: Xospata
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Aptose intends to use the net proceeds to support clinical trials for HM43239 (tuspetinib), a once daily oral therapy being studied as monotherapy and in combination therapy in Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $8.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 26, 2024
Details:
FP-1305 (bexmarilimab) is a monoclonal antibody that binds to Clever-1. It is being evaluated in phase 1/2 clinical trials for the treatment of acute myeloid leukemia, myelodysplastic syndromes & chronic myelomonocytic leukemia.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
FP-1305 (bexmarilimab) is a CLEVER-1 binder, which is under phase 1/2 clinical development in combination with azacitidine & venetoclax for the treatment of acute myeloid leukemia, myelodysplastic syndromes & chronic myelomonocytic leukemia.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
VIP152 (enitociclib) is a highly selective CDK9 inhibitor that prevents activation of RNA polymerase II, resulting in reduction of known oncogenes MYC and MCL1. It is currently in Phase 1/2 trials combination with venetoclax and prednisone for the treatment of Lymphoma.
Lead Product(s): Enitociclib,Venetoclax,Prednisone
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2024
Details:
SL-172154 (SIRPα-Fc-CD40L) is an investigational ARC fusion protein designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor to bolster an anti-tumor immune response in patients with advanced cancer.
Lead Product(s): SL-172154,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SL-172154
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
SNDX-5613 (revumenib) is a highly selective, oral menin inhibitor which is under phase 1 clinical development for the treatment of patients with Acute Leukemias.
Lead Product(s): Revumenib,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
SELECT-AML-1 is evaluating the safety and efficacy of SY-1425 (tamibarotene) in combination with venetoclax and azacitidine compared to venetoclax and azacitidine in patients patients with acute myeloid leukemia and RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.
Lead Product(s): Bexmarilimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory (r/r) acute myeloid leukemia.
Lead Product(s): GFH009,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SLS009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
The proceeds will be used for Aptose’s lead hematology drug, tuspetinib, formerly HM43239, an orally active small molecule inhibitor of FLT3, currently in Phase 1/2 trial in which patients with R/R AML receive tuspetinib monotherapy or in combination with venetoclax.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hanmi Pharmaceutical
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 06, 2023
Details:
GS-4721 (magrolimab), a potential, first-in-class investigational monoclonal antibody that binds to CD47 and block the inhibitory CD47-signal regulatory protein (SIRPα) interaction, is being developed in several hematologic cancers and solid tumor malignancies.
Lead Product(s): Magrolimab,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: GS-4721
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
ALX148 (evorpacept) is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin, being developed for the treatment of myelodysplastic syndromes.
Lead Product(s): Evorpacept,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
GFH009 is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of acute myeloid leukemia (AML).
Lead Product(s): GFH009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
ME-522 (voruciclib) is an orally administered cyclin-dependent kinase 9 (“CDK9”) inhibitor with potential to treat Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
Lead Product(s): Voruciclib,Venetoclax
Therapeutic Area: Oncology Product Name: ME-522
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Imbruvica (ibrutinib) is a small-molecule inhibitor of BTK, it was granted NICE approval in combination with venetoclax as first-line treatment option for chronic lymphocytic leukaemia.
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2023
Details:
HM43239 (tuspetinib), once daily oral agent which inhibts SYK, JAK1/2, FLT3, and other kinases operative in AML, by inhibiting tyrosine kinase, tucatinib exerts anti-tumor activity, reducing the size of HER-2 positive breast cancer tumors.
Lead Product(s): Tuspetinib,Venetoclax
Therapeutic Area: Oncology Product Name: HM43239
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
APVO436 is a bispecific CD3xCD123 ADAPTIR currently in Phase 1b development in a multi-center, multi-cohort trial designed to evaluate safety, tolerability and efficacy in combination therapy and monotherapy for patients with AML.
Lead Product(s): APVO436,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Evorpacept in combination with azacitidine and venetoclax was generally well tolerated (N=14) with no maximum tolerated dose identified and a maximum administered dose of 60 mg/kg Q4W.
Lead Product(s): Evorpacept,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Pirtobrutinib (LOXO-305), is an investigational, highly selective, reversible (non-covalent) inhibitor of Bruton's tyrosine kinase (BTK). Pirtobrutinib was developed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate.
Lead Product(s): Pirtobrutinib,Venetoclax,Rituximab
Therapeutic Area: Oncology Product Name: LOXO-305
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
